期刊文献+

脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响

Effects of lienal polypeptide injection combined with cetuximab and mFOLFOX6 regimen on quality of life and expressions of TRF1 and TRF2 in rectal cancer patients with liver metastases
下载PDF
导出
摘要 目的探讨脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及端粒重复序列结合因子1(TRF1)、端粒重复序列结合因子2(TRF2)表达的影响。方法选取2019年1月至2021年12月收治的80例直肠癌肝转移患者为研究对象,以随机数字表法将其分为对照组与观察组,各40例。对照组采用西妥昔、m FOLFOX6方案治疗,观察组在对照组基础上加用脾多肽注射液治疗。比较两组的治疗效果。结果治疗后,观察组的生理职能、生理机能、躯体疼痛、一般健康状况、精力、社会功能、精神健康、情感职能评分均高于对照组(P<0.05)。治疗后,观察组的可溶性白细胞介素-6受体(sIL-6R)、白细胞介素-6(IL-6)水平低于对照组,自然杀伤(NK)细胞高于对照组(P<0.05)。治疗后,观察组的TRF1表达水平高于对照组,TRF2表达水平低于对照组(P<0.05)。结论脾多肽注射液联合西妥昔、mFOLFOX6方案治疗直肠癌肝转移能够提高患者的生存质量,改善免疫力,并调节TRF1、TRF2表达水平,值得推广。 Objective To explore the effects of lienal polypeptide injection combined with cetuximab and mFOLFOX6 regimen on quality of life and expressions of telomeric repeat factor 1(TRF1)and telomeric repeat factor 2(TRF2)in rectal cancer patients with liver metastases.Methods A total of 80 rectal cancer patients with liver metastasis admitted from January 2019 to December 2021 were selected as the study objects and divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with cetuximab and mFOLFOX6 regimen,and the observation group was treated with lienal polypeptide injection on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the scores of role-physical,physical functioning,bodily pain,general health,vitality,social functioning,mental health and role-emotional in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of soluble inferleukin-6 receptor(sIL-6R)and inferleukin-6(IL-6)in the observation group were lower than those in the control group,and the natural killer(NK)cell was higher than that in the control group(P<0.05).After treatment,the expression level of TRF1 in the observation group was higher than that in the control group,and the expression level of TRF2 was lower than that in the control group(P<0.05).Conclusion Lienal polypeptide injection combined with cetuximab and mFOLFOX6 regimen in the treatment of liver metastasis of rectal cancer can improve the quality of life of patients,ameliorate immunity,and regulate the expression levels of TRF1 and TRF2,which is worthy of promotion.
作者 刘炫鳞 买佳琪 马文兵 LIU Xuanlin;MAI Jiaqi;MA Wenbing(the First People's Hospital of Xianyang,Xianyang 712000;the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
出处 《临床医学研究与实践》 2023年第25期29-32,共4页 Clinical Research and Practice
基金 陕西省2021年科技计划项目(No.2021SF-130)。
关键词 脾多肽注射液 西妥昔 mFOLFOX6方案 直肠癌肝转移 lienal polypeptide injection cetuximab mFOLFOX6 regimen rectal cancer with liver metastasis
  • 相关文献

参考文献15

二级参考文献130

  • 1文进,李幼平.Meta分析中效应尺度指标的选择[J].中国循证医学杂志,2007,7(8):606-613. 被引量:127
  • 2National Comprehensive Cancer Network. No. 12/09/14. NCCN Clinical Practice Guidelines in Oncology Rectal Cancer Version 2. 2015 [ S]. USA: National Comprehensive Cancer Network. [2015-2-20]. http://guide, medlive. cn/guideline/7460.
  • 3National Comprehensive Cancer Network. No. 10/03/14. NCCN Clinical Practice Guidelines in Oncology Colon Cancer Version 2. 2015 [S]. USA: National Comprehensive Cancer Network. [2015-2-20]. http ://guide. medlive. cn/guideline/7015.
  • 4National Comprehensive Cancer Network. No. 07/01/13. NCCN Clinical Practice Guidelines in Ontology Colorectal Cancer Version 2. 2013 [ S ]. USA: National Comprehensive Cancer Network. [ 2015-2-20]. http://guide, medlive, czr/guideline/preview/1/ 4774.
  • 5Zhang D,Ye J,Xu T, et al. Treatment related severe and fatal ad- verse events with cetuximab in colorectal cancer patients: a meta- analysis[J]. J Chemother, 2013, 25 (3): 170-175.
  • 6Department of Health and Human Services. No. 09-5410 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.3 [ S]. USA: National Institute of Health National Cancer Institute. [2014-12-15 ]. http ://guide. medlive, en/guideline/7697.
  • 7Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy accord- ing to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [ J ]. Ann Oncol, 2011, 22 (7) : 1535-1546.
  • 8Jocefin H, Suresh GN, Michelle RM, et al. Comparison of FOL- FIRI with or without cetuximab in patients with resected stage IIl colon cancer; NCCTG (Alliance) Intergroup Trial N0147 [J]. Clin Colorectal Cancer, 2014, 13(2) :100-109.
  • 9Alberto FS, Joan M, Louis F, et al. EPIC :phase III trial of cetux- imabplus irinotecanafter fluoropyrimidine and oxaliplatinfailure in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(14) : 2311-2319.
  • 10Alice D, David C, Josep T, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) [J]. J Clin Oncol, 2012, 30 (14) : 1620-1627.

共引文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部